International Stem Cell Corporation  (ISCO)
Other Ticker:  
Price: $0.1090 $0.00 0.000%
Day's High: $0.109 Week Perf: 21.11 %
Day's Low: $ 0.11 30 Day Perf: 55.71 %
Volume (M): 1 52 Wk High: $ 0.17
Volume (M$): $ 0 52 Wk Avg: $0.11
Open: $0.11 52 Wk Low: $0.05

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is a biotechnology company that specializes in the development and commercialization of human stem cell-based technologies and therapies. The company is focused on utilizing its proprietary parthenogenetic stem cell technology to create functional cells for a variety of applications in the field of regenerative medicine. ISCO's innovative approach allows for the creation of pluripotent stem cells without the use of fertilized embryos, making it ethically and politically advantageous. The company's main areas of research include stem cell-based treatments for various diseases, such as Parkinson's disease, liver diseases, and corneal blindness. ISCO is committed to advancing stem cell research and translating it into effective therapies for the benefit of patients worldwide.

   Company Address: 9745 Businesspark Ave San Diego 92131 CA
   Company Phone Number: 940-6383   Stock Exchange / Ticker: ISCO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

International Stem Cell Corporation

International Stem Cell Corporation Reports a Narrow Margin of $0.02 Shortfall Per Share in Third Quarter of 2023

The stock market provides a wealth of opportunities for investors, with companies' financial performance serving as a key indicator of their potential for growth and profitability. International Stem Cell Corporation (ISCO) recently released its third-quarter results for 2023, displaying a mixed bag of results. Despite a fall in earnings per share and increased net shortfall, the company reported a significant rise in revenue. This article aims to dissect ISCO's financial performance in Q3 2023 and highlight some interesting observations.
Earnings per Share and Revenue:
ISCO experienced a decline in earnings per share, dropping from $0.03 per share to $-0.02 per share when compared to the previous reporting season. This decline should be viewed as a matter of concern for potential investors, as it indicates a loss in profitability. However, in a positive development, the company?s revenue witnessed double-digit growth of approximately 15.854%, increasing from $1.70 million in the comparable reporting season last year to $1.97 million. Sequentially, revenue advanced by 7.17% from the previous quarter.

International Stem Cell Corporation

International Stem Cell Corporation Breaks the Mold with Robust Revenue Growth in Q2 2023

International Stem Cell Corporation (ISCO) has experienced a decline in its stock performance over the last five trading days, resulting in a year-to-date performance loss of 26.94%. Presently, the company's shares are trading around 42.2% below its 52-week average. Examining the company's recently released financial results for the period ending June 30, 2023, sheds light on the potential impact these figures may have on ISCO's future.
1. Stable Income per Share but Impaired Revenue:
ISCO's income per share remained unchanged at $0.03 compared to the same period last year and the previous financial reporting period. This stability suggests a consistent performance by the Major Pharmaceutical Preparations company in generating earnings for shareholders.

International Stem Cell Corporation

Major Pharmaceutical Preparations Company Generates $2.086 Million in Revenue during the Latest Fiscal Period

International Stem Cell Corporation (ISCO) is a major player in the field of stem cell research, with a focus on developing revolutionary new treatments for a variety of diseases and conditions. The company has recently released its financial results for the most recent fiscal period, showing a zero gain of $0.00 per share, which is down from the $0.00 per share that was achieved last year.
Despite this relatively flat financial performance, ISCO has made impressive strides in its research and development efforts in recent years, developing cutting-edge stem cell-based technologies that have the potential to revolutionize the way we approach medical treatment. The company's proprietary parthenogenetic stem cell technology is particularly promising, allowing for the creation of stem cells that are genetically diverse and immune-compatible with the majority of the population.


International Stem Cell's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com